-
Thematic Analysis
NewState of the Biopharmaceutical Industry 2024 Edition (Mid-Year Update) – Thematic Intelligence
Reasons to buy the ‘State of the Biopharmaceutical Industry 2024’ thematic intelligence report: Highlight the business environment and the industry, regulatory, and macroeconomic trends that are going to shape the biopharmaceutical industry in the next 12 months. Benchmark the impact of major themes on the biopharmaceutical industry in the next 12 months, Identify themes that will have the greatest positive or negative impact in the coming months. Comprehend the opinions of industry respondents on these themes. Predict the industry’s growth prospects...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NKX-019 in Refractory Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NKX-019 in Refractory Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NKX-019 in Refractory Chronic Lymphocytic Leukemia (CLL) Drug...
-
Product Insights
NewNet Present Value Model: Moderna Inc’s mRNA-3927
Empower your strategies with our Net Present Value Model: Moderna Inc's mRNA-3927 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Afamitresgene Autoleucel in Synovial Sarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Afamitresgene Autoleucel in Synovial Sarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Afamitresgene Autoleucel in Synovial Sarcoma Drug Details: ADPA-2M4 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Uzatresgene Autoleucel in Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Uzatresgene Autoleucel in Ovarian Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Uzatresgene Autoleucel in Ovarian Cancer Drug Details: uzatresgene autoleucel (ADP-A2M4CD8)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Uzatresgene Autoleucel in Fallopian Tube Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Uzatresgene Autoleucel in Fallopian Tube Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Uzatresgene Autoleucel in Fallopian Tube Cancer Drug Details: uzatresgene...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Uzatresgene Autoleucel in Peritoneal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Uzatresgene Autoleucel in Peritoneal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Uzatresgene Autoleucel in Peritoneal Cancer Drug Details: uzatresgene autoleucel (ADP-A2M4CD8)...
-
Product Insights
NewNet Present Value Model: Adaptimmune Therapeutics Plc’s Afamitresgene autoleucel
Empower your strategies with our Net Present Value Model: Adaptimmune Therapeutics Plc's Afamitresgene autoleucel report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Apatinib Mesylate in Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Apatinib Mesylate in Melanoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Apatinib Mesylate in Melanoma Drug Details: Apatinib Mesylate (Aitan) is an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Apatinib Mesylate in Hepatocellular Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Apatinib Mesylate in Hepatocellular Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Apatinib Mesylate in Hepatocellular Carcinoma Drug Details: Apatinib Mesylate (Aitan)...